BK 초청세미나 (부산대, 권상모교수)
생명과학과
2012-04-24
세미나 장소 : K407
세미나 일시 : 2012.04.26. (16:30)
세미나 발표자 : 부산대, 권상모교수.
세미나 일시 : 2012.04.26. (16:30)
세미나 발표자 : 부산대, 권상모교수.
Two Promising Strategies for Adult Stem Cells Therapy for Ischemic Vascular Regeneration
Stem cells offer significant therapeutic promise for the treatment of ischemic disease. However, stem cells transplanted into ischemic tissue exhibit limited therapeutic efficacy sue to poor engraftment in vivo. Several strategies for improving the survival and engraftment of stem cells in ischemic tissue have been developed including transplantation in combination with growth factor delivery, genetic modification of stem cells, and the use cell-transplantation scaffolds. Here, we examined effect of human endothelial progenitor cells (hEPCs) hybrid spheroid on therapeutic efficacy in hindlimb ischemia model. hEPCs were cultured in spheroid or hybrid spheroid. Hybrid spheroid enhancing secretion of both angiogenic and anti-apoptotis factors compared to spheroids. Following intramuscular transplantation to ischemic hindlimbs of mouse, hybrid spheroids showed improved cell survival, angiogenic factor secretion, neovascularization, and limb survival as compared to spheroids. The results suggest that hybrid spheroid-based hEPC delivery may be a simple and effective strategy for increasing the therapeutic efficacy of hEPCs. In the next experiment, we examined effect of genistein on therapeutic efficacy in acute myocardic ischemia model. Genistein-induced hEPC proliferation and migration was mediated by increased focal adhesion kinase (FAK), Src and ERK phosphorylation. In a mouse myocardial ischemia model, injection of genistein pretreatment hEPC into myocardial ischemic site, thereby enhanced neovascularization and decreased myocardial fibrosis. These data suggest that preculturing hEPC under genistein treatment conditions prior to transplantation improves their tissue regenerative potential. This study may provide an innovative medical approach that complement current stem cell therapy for ischemic disease.